WO1998006690B1 - USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM - Google Patents

USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM

Info

Publication number
WO1998006690B1
WO1998006690B1 PCT/EP1997/004309 EP9704309W WO9806690B1 WO 1998006690 B1 WO1998006690 B1 WO 1998006690B1 EP 9704309 W EP9704309 W EP 9704309W WO 9806690 B1 WO9806690 B1 WO 9806690B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
amide
alcohol
butyrolactone
Prior art date
Application number
PCT/EP1997/004309
Other languages
French (fr)
Other versions
WO1998006690A1 (en
Filing date
Publication date
Priority claimed from IT96MI001732A external-priority patent/IT1283782B1/en
Priority to US09/242,048 priority Critical patent/US6436998B1/en
Priority to AT97941921T priority patent/ATE215065T1/en
Priority to SI9730343T priority patent/SI0932597T1/en
Priority to CA002263328A priority patent/CA2263328C/en
Priority to JP50937298A priority patent/JP4259615B2/en
Application filed filed Critical
Priority to EP97941921A priority patent/EP0932597B1/en
Priority to DE69711411T priority patent/DE69711411T2/en
Priority to AU43790/97A priority patent/AU4379097A/en
Priority to HU9902437A priority patent/HU228595B1/en
Priority to DK97941921T priority patent/DK0932597T3/en
Publication of WO1998006690A1 publication Critical patent/WO1998006690A1/en
Publication of WO1998006690B1 publication Critical patent/WO1998006690B1/en

Links

Abstract

The present invention relates to the use of η-hydroxybutyric acid amides, herein referred to as GHB, in the treatment of drug addiction, such as heroin, morphine and psychoactive substances and in the treatment of alcoholism, more particularly in reducing chronic alcoholics' desire for and habit of consuming alcoholic drinks and in the treatment of the syndrome of abstinence from alcohol.

Claims

AMENDED CLAIMS
[received by the International Bureau on 9 March 1998 (09.03.98); original claims 24-33 replaced by amended claims 24-32; remaining claims unchanged (3 pages)]
- and the amide of group c) is compound 16) of formula (I), in which Q=CH3, T^T^H, n=1 , R^phenyl, R2=H. 24. The composition as claimed in claim 23, wherein the amide is selected from compound 5), 7), 14) and compound 15). 25. The composition as claimed in claim 18 to be administered by the oral or parenteral way. 26. Amide of formula (I) Q I R20-(CH2),-CO-N-CCT1TJπ-R1 (I) where Q=H, T^T^H, n=1 , R^ethyl, R2=H compound 2); where Q=H, T^T^H, n=1 , R1=4-methylphenyl, R2=CH3 compound 7) where Q=H, T1=T2=H, n=1 , R^S.δ-dimethoxyphenyl, R2=H compound 8); where Q=H, T,=T2=H, n=1 , R^-pyridyl, R2=H compound 9); where Q=H, T^T^H, n=1 , R^phenyl, R2=CH3 compound 10); where Q=H, T1=T2=H, n=1 , R1=4-chlorophenyl, R2=CH3 compound 11 ); where Q=H, T^T^H, n=1 , R1=4-methylphenyl, R2=CH3CH2- compound 12); where Q=H, T^T^H, n=1 , R1=4-methylphenyl, R2=CH3CH2CH2- compound 13); where Q=H, T^T^H, n=1 , R^l-naphthyl, R2=CH3 compound 14); where Q=H, T1=T2=Hf n=1 , R1=4-CF3-phenyl, R2=CH3 compound 15); where Q=CH3, T^T^H, n=1 , R^phenyl, R2=H compound 16). 27. The amide as claimed in claim 26, selected from compound 7) and compound 14). 28. Process for the preparation of an amide of formula (I) Q
Figure imgf000003_0001
where R2 is an alkyl and the other substituents are as defined in claim 1 , comprising the following steps: a) treating γ-butyrolactone with an alcohol of formula R2OH (III) in which R2 is an alkyl, in the presence of an ortho-formiate of formula (IV) 34
H-C(OR2)3 (IV) in which R2 is as defined above for the alcohol of formula (III), in the presence of an acid catalyst, to give an ester of formula (V) R20-(CH2)3-COOR2 (V) in which R2 is as defined above for the alcohol of formula (III); b) treating the ester of formula (V) obtained in a) with an amine of formula (VI) Q I H-N-tCT ^-R, (VI) where R1 f Q, T1 ( T2, and n are as defined above for formula (I), in the presence of an ammonium halide. 29. The process as claimed in claim 28, wherein R2 is C1-C3 alkyl. 30. The process as claimed in claim 28, wherein step a) utilizes ortho-formiate in a quantity of 1.5-2 mol per mol γ-butyrolactone, an alcohol of formula (III) as solvent; an acid catalyst consisting of an inorganic acid in a quantity of 0.05-0.5 equivalent in respect of γ-butyrolactone, a reaction temperature ranging from 30°C to 100°C; step b) is carried out in the absence of solvent, at a temperature ranging from 100°C to 200°C, at a pressure ranging from atmospheric to autogenous pressure (obtained by operating in a bomb), with ammonium halide in a quantity ranging from 0.01 to 0.1 equivalent in respect of the substrate. 31. The process as claimed in claim 28, wherein step a) is carried out with a catalyst consisting of sulphuric acid in a quantity of 0.1 equivalent, at a temperature ranging from +50°C to +80°C; in step b) the catalyst is NH4CI, the temperature is 160°C to 170°C, and the reaction is carried out in a bomb. 32. Process for the preparation of an amide of formula (l)B Q I HO-(CH2)3-CO-N-[CT1T2]n-R1 (l)B in which R, is an aromatic heterocycle, and Q, T1 f T2 and n are as defined for formula (I) in claim 1 , in which γ-butyrolactone reacted with the corresponding amine of formula (II) Q I H-N-fCT Jn-R, (II)
in which R1( Q, T1t T2 and n are as defined above, by contacting the reagents in equimolar amounts in the absence of solvent at a temperature ranging from 100°C to 200°C, at atmospheric pressure.
PCT/EP1997/004309 1996-08-09 1997-08-07 USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM WO1998006690A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK97941921T DK0932597T3 (en) 1996-08-09 1997-08-07 Use of gamma-hydroxybutyric acid amides for the treatment of drug dependence and especially alcoholism
AT97941921T ATE215065T1 (en) 1996-08-09 1997-08-07 USE OF GAMMA-HYDROXYBUTTERIC AMIDES IN THE TREATMENT OF DRUG DEPENDENCE AND ESPECIALLY ALCOHOLISM
SI9730343T SI0932597T1 (en) 1996-08-09 1997-08-07 Use of gamma-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
CA002263328A CA2263328C (en) 1996-08-09 1997-08-07 Use of .gamma.-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
JP50937298A JP4259615B2 (en) 1996-08-09 1997-08-07 Use of .GAMMA.-hydroxybutyric acid amide in drug use and especially in alcoholic dormitories.
US09/242,048 US6436998B1 (en) 1996-08-09 1997-08-07 Use of gamma-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
EP97941921A EP0932597B1 (en) 1996-08-09 1997-08-07 Use of gamma-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
DE69711411T DE69711411T2 (en) 1996-08-09 1997-08-07 USE OF GAMMA HYDROXYBUTTERIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND ESPECIALLY ALCOHOLISM
AU43790/97A AU4379097A (en) 1996-08-09 1997-08-07 Use of gamma-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
HU9902437A HU228595B1 (en) 1996-08-09 1997-08-07 Gamma-hydroxybutyric acid amides, process to prepare them, use gamma-hydroxybutyric acid amides, and pharmaceuticals contg. them for the treatmant of drug abusing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI96A001732 1996-08-09
IT96MI001732A IT1283782B1 (en) 1996-08-09 1996-08-09 USE OF AMIDES OF GAMMA-HYDROXYBUTYRIC ACID IN THE TREATMENT OF TOXIC ADDICTION, AND IN PARTICULAR IN ALCOHOLISM

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/013,971 Division US6770784B2 (en) 1996-08-09 2001-12-11 Use of γ-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism

Publications (2)

Publication Number Publication Date
WO1998006690A1 WO1998006690A1 (en) 1998-02-19
WO1998006690B1 true WO1998006690B1 (en) 1998-04-16

Family

ID=11374795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/004309 WO1998006690A1 (en) 1996-08-09 1997-08-07 USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM

Country Status (13)

Country Link
US (2) US6436998B1 (en)
EP (1) EP0932597B1 (en)
JP (1) JP4259615B2 (en)
AT (1) ATE215065T1 (en)
AU (1) AU4379097A (en)
CA (1) CA2263328C (en)
DE (1) DE69711411T2 (en)
DK (1) DK0932597T3 (en)
ES (1) ES2174287T3 (en)
HU (1) HU228595B1 (en)
IT (1) IT1283782B1 (en)
PT (1) PT932597E (en)
WO (1) WO1998006690A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) * 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
FR2827859B1 (en) 2001-07-30 2005-09-23 Lipha 4- (ARYLTHIO) - OR 4- (HETEROARYLTHIO) -BUTYRIC DERIVATIVES IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DIABETES
AU2003295393A1 (en) * 2002-11-01 2004-06-07 Baylor Research Institute Ghb treatment methods
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
EP2062875A1 (en) * 2007-11-13 2009-05-27 LABORATORIO FARMACEUTICO C.T. S.r.l. New polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
BR112012024019B1 (en) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc CONTROLLED RELEASE DOSAGE FORM FOR ORAL ADMINISTRATION
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
ITMI20132041A1 (en) * 2013-12-06 2015-06-07 Ct Lab Farm Srl DERIVATIVES OF THE ACID RANGE-HYDROXYBUTIRRIC, THEIR PREPARATION AND THEIR MEDICAL USE.
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
ITUB20152860A1 (en) 2015-08-04 2017-02-04 Laboratorio Farm C T S R L Selected amide of? -Hydroxybutyric acid and its uses in the treatment of alcohol abuse
ITUA20164040A1 (en) * 2016-06-01 2017-12-01 Laboratorio Farm C T S R L PROCEDURE FOR THE PREPARATION OF POLIMORFO A
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
KR20210094513A (en) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 Alcohol-Resistant Drug Formulations
JP7553453B2 (en) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド Gamma-hydroxybutyrate compositions with improved pharmacokinetics under fed conditions - Patents.com
WO2023126076A1 (en) 2022-01-03 2023-07-06 Laboratorio Farmaceutico C.T. S.R.L. Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940258A (en) * 1971-11-26 1976-02-24 Gaf Corporation Method for controlling aquatic weeds with N-phenylalkyl-γ-hydroxybutyramide
JPS6016432B2 (en) * 1977-07-26 1985-04-25 グレラン製薬株式会社 Heterocyclic compounds and their production methods
ES2052619T3 (en) * 1987-02-23 1994-07-16 Ono Pharmaceutical Co A PROCEDURE FOR THE PREPARATION OF THE NEW THIAZOLIDINE DERIVATIVES.
IT1217783B (en) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab USE OF SALO DELL, BUTYRIC HYDROXIC ACID RANGE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS SUITABLE FOR USE IN THE ALCOHOLIC THERAPY AND RELATED COMPOSITIONS
IT1248588B (en) 1991-06-28 1995-01-19 Gaetano Crepaldi PHARMACEUTICAL COMPOSITIONS FOR THERAPY OF ABSTINENCE, "CRAVING", DEPENDENCE ON AMAZING SUBSTANCES, PSYCHOACTIVE SUBSTANCES, NICOTINE AND FOOD DISORDERS.
EP0763016B1 (en) * 1994-06-01 2000-01-26 Axys Pharmaceuticals, Inc. Compositions and methods for treating mast-cell mediated conditions
CZ272296A3 (en) * 1995-09-18 1997-04-16 Sankyo Co Novel derivatives of urea exhibiting acat inhibition activity, their preparation and therapeutic and prophylactic application
ES2237850T3 (en) * 1997-10-14 2005-08-01 Mitsubishi Pharma Corporation PIPERAZINE COMPOUNDS AND THEIR MEDICINAL USE.

Similar Documents

Publication Publication Date Title
WO1998006690B1 (en) USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM
EP1062999A3 (en) Method for removing carbon dioxide from combustion exhaust gas
SK81599A3 (en) Process to prepare tolterodine
DE19882892T1 (en) Preparation of 3-substituted adenines and imidazopyridines
KR880012526A (en) l-phenyl-3-naphthalenyloxypropanamine
KR950032058A (en) Continuous production method of pure acrylic acid
RU97102150A (en) METHOD FOR PRODUCING 2-HYDROXY-4-METHYLBUT OTHER ACID (METHIONINE HYDROXYANALOGUE, GAM), GAM AND ITS APPLICATION
WO1994020463B1 (en) Novel distamycin analogues
WO1999003817B1 (en) Aliphatic propargylamines as cellular rescue agents
WO2000033839B1 (en) Non-peptide antagonists of glp-1 receptor and methods of use
ATE165810T1 (en) N-SUBSTITUTED DERIVATIVES OF N-METHYL-3-(P-TRIFLUORMETHYLPHENOXY)-3-PHENYLPROPYLAMIN AND METHOD FOR THE PRODUCTION THEREOF
DE69803537D1 (en) Continuous process for the production of diazomethane
CN1361102A (en) Method of producing imidacloprid
NZ521201A (en) Method for the preparation of citalopram
WO2006103696B1 (en) Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives
CA2469783A1 (en) A method for preparing a sensitised emulsion explosive
EP0860417A3 (en) Liquid crystalline compounds and process for producing the same
KR970074748A (en) Process for preparing 3-amino substituted crotonate
KR900000349A (en) Phenothiazine, a process for its preparation and a composition comprising the same
WO2003036257A3 (en) Immobilizing biological molecules
RU2036910C1 (en) Method of synthesis of 2-piperazinones
KR860003231A (en) Method for preparing 2-cyanobenz imidazole derivative
WO2002000625A3 (en) Process for the preparation of quinoline derivatives
RU96100855A (en) METHOD OF OBTAINING 5-SUBSTITUTED 2-CHLORPYRIDINE
US11247167B2 (en) Scavenging system including at least one mixed acetal compound to remove hydrogen sulfide and/or mercaptans from a fluid stream